![conference banner](/images/conference-banner.jpeg)
Abstract
Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Current Pharmaceutical Design
Title: Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals
Volume: 12 Issue: 30
Author(s): Kiichi Ishiwata and Kenji Hashimoto
Affiliation:
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Abstract: Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Export Options
About this article
Cite this article as:
Ishiwata Kiichi and Hashimoto Kenji, Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559614
DOI https://dx.doi.org/10.2174/138161206778559614 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Statins: Are They All the Same?
Current Drug Therapy Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Twitter Trends Reveals: Focus of Interest in the Sleep Trend Analytics on Response to COVID-19 Outbreak
Current Psychiatry Research and Reviews Current Trends on Antipsychotics: Focus on Asenapine
Current Medicinal Chemistry Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction
CNS & Neurological Disorders - Drug Targets Early Cerebral Infarction Following Aneurysmal Subarachnoid Hemorrhage: Frequency, Risk Factors, Patterns, and Prognosis
Current Neurovascular Research Waveform Analysis of Non-Oscillatory Independent Components in Single-Trial Auditory Event-Related Activity in Healthy Subjects and Alzheimers Disease Patients
Current Alzheimer Research Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Pain-Related Behavior and Brain Activation in a Cynomolgus Macaque Model of Postoperative Pain
CNS & Neurological Disorders - Drug Targets Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research Lessons from Darwin: Evolutionary Biologys Implications for Alzheimers Disease Research and Patient Care
Current Alzheimer Research Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Meet Our Editorial Board Member:
Current Alzheimer Research Predicting Citrullination Sites in Protein Sequences Using mRMR Method and Random Forest Algorithm
Combinatorial Chemistry & High Throughput Screening Updates on Genome-Wide Association Findings in Eating Disorders and Future Application to Precision Medicine
Current Neuropharmacology The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) SCIENTIFIC PAPERS
Adolescent Psychiatry Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery